Early patient stratification and predictive biomarkers in drug discovery and development

Advances in Experimental Medicine and Biology

Volumn 736, Issue , 2012, Pages 645-653

  Laifenfeld, Daphna ^a   Drubin, David A ^a   Catlett, Natalie L ^a   Park, Jennifer S ^a   Van Hooser, Aaron A ^a   Frushour, Brian P ^a   De Graaf, David ^a   Fryburg, David A ^a   Deehan, Renée ^a  

^a Selventa   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BIOLOGICAL MARKER; ESTROGEN RECEPTOR; INFLIXIMAB; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA;

ALGORITHM; ARTICLE; BREAST CANCER; CASE STUDY; DRUG EFFICACY; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE NUMBER; HER2 GENE; HUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEOMICS; SYSTEMS BIOLOGY; TREATMENT RESPONSE; ULCERATIVE COLITIS; VALIDITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862964489     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-7210-1_38     Document Type: Article

References (15)

1. Brown D, Superti-Furga G (2003) Rediscovering the sweet spot in drug discovery. Drug Discov Today 8(23):1067-1077 (Pubitemid 38124472)
2. DiMasi J (2002) The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 20(Suppl 3):1-10
3. DiMasi J, Hansen R, Grabowski H (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22(2):151-185 (Pubitemid 36279392)
4. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365:1687-1717
5. Hofmann M, Stoss O, Gaiser T, Kneitz H, Heinmöller P, Gutjahr T, Kaufmann M, Henkel T, Rüschoff J (2008) Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. JClin Pathol 61(1):89-94 (Pubitemid 351158232)
6. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes J,Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765
7. Tan P (2009) Divide and conquer: progress in the molecular stratification of cancer. Yonsei Med 50(4):464-473
8. Naylor S, Cole T (2010) Overview of companion diagnostics in the pharmaceutical industry. Drug Discov World Spring Edition: 67-79
9. Arijs I, De Hertogh G, Lemaire K, Quintens R, Van Lommel L, Van Steen K, Leemans P, Cleynen I, Van Assche G, Vermeire S, Geboes K, Schuit F, Rutgeerts P (2009) Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One 4(11):e7984
10. Arjis I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K, Leemans P, De Hertogh G, Lemaire K, Ferrante M, Schnitzler F, Thorrez L, Ma K, Song XY, Maranoo C, Van Assche G, Vermeire S, Geboes K, Schuit F, Baribaud F, Rutgeerts P (2009) Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 58(12):1612-1619
11. Kang CP, Lee KW, Yoo DH, Kang C, Bae SC (2005) The influence of a polymorphism at position-857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology 44(4):547-552 (Pubitemid 41511149)
12. De Vries N, Tak PP (2005) The response to anti-TNF-alpha treatment: gene regulation at the bedside. Rheumatology 44(4):547-552
13. Shetty A, Forbes A (2002) Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn's disease. Am J Pharmacogenom 2(4):215-221 (Pubitemid 35429311)
14. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286(5439):531-537
15. McLendon R et al (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061-1068